文献速递主动脉疾病

持续2型内漏患者D-二聚体动态变化与动脉瘤扩大的预后价值

Prognostic Value of D-Dimer Dynamics for Aneurysm Enlargement in Patients With Persistent Type 2 Endoleaks After Endovascular Aneurysm Repair.
PubMed 文献 · J Endovasc Ther · 2026-07-19

本研究为单中心回顾性队列,纳入118例EVAR术后12个月确认孤立性持续2型内漏且随访>2年的患者,按D-二聚体轨迹分为持续低(<5.3 µg/mL)、转为高(≥13.5 µg/mL)和中间组。转为高组动脉瘤扩大风险显著高于持续低组(调整HR=4.76,95%CI 1.62-14.00,P=.005),GEE分析显示剂量反应关系。

要点

  • 持续低D-二聚体(<5.3 µg/mL)与动脉瘤囊稳定相关。
  • D-二聚体升至≥13.5 µg/mL提示动脉瘤扩大高风险,需密切随访。
  • 动态监测D-二聚体可能辅助影像学 surveillance,但需前瞻性验证。

核心结论

  • 持续2型内漏患者中,D-二聚体动态轨迹与5年内动脉瘤扩大独立相关。
  • D-二聚体持续<5.3 µg/mL者囊稳定,升至≥13.5 µg/mL者扩大风险更高。

研究设计与样本

  • 回顾性单中心队列研究,纳入2007-2022年择期EVAR后12个月确认孤立性持续2型内漏、随访>2年且有年度D-二聚体数据的连续患者。
  • 共纳入118例患者,主要结局为5年内动脉瘤囊直径增加≥5 mm。

主要发现

  • 118例中43例(36.4%)发生动脉瘤扩大。
  • Kaplan-Meier分析显示转为高组无扩大生存率显著更低(整体log-rank P=.002)。
  • 轨迹Cox回归中,转为高组较持续低组动脉瘤扩大风险显著增加(调整HR=4.76,95%CI 1.62-14.00,P=.005)。
  • GEE敏感性分析确认剂量反应关系,高D-二聚体关联最强(OR=3.45,95%CI 1.69-7.05,P<.001)。

关键数值与推荐

  • D-二聚体轨迹分类:持续低为全程<5.3 µg/mL;转为高为任意时点≥13.5 µg/mL;中间为其他所有情况。
  • 动脉瘤扩大定义为囊直径增加≥5 mm。
  • 多变量模型调整慢性肾病、肠系膜下动脉通畅及通畅腰动脉数量(≥6)。

临床怎么用

  • 对持续2型内漏患者,可考虑动态监测D-二聚体辅助影像学随访。
  • D-二聚体<5.3 µg/mL提示扩大风险低,≥13.5 µg/mL提示高风险需更密切随访。
  • 该策略需前瞻性验证后方可用于临床决策。

局限性

  • 回顾性单中心设计,轨迹分类为回顾性定义。
  • 样本量有限(118例),需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Persistent type 2 endoleaks (pT2ELs) following endovascular aortic aneurysm repair (EVAR) pose surveillance challenges. Although previous studies demonstrated that low D-dimer levels at single time points indicate lower risk of aneurysm enlargement (AnE), the value of longitudinal D-dimer monitoring remains unexplored. This study examined associations between D-dimer dynamics and AnE in patients with pT2ELs. METHODS: This is a retrospective single-center cohort study. Consecutive patients undergoing elective EVAR (2007-2022) were reviewed. Inclusion criteria were isolated pT2ELs confirmed at 12 months, >2 years of follow-up, and available annual D-dimer data. Primary outcome was AnE (≥5 mm sac diameter increase) within 5 years. D-dimer trajectories were retrospectively classified as consistently low (<5.3 µg/mL throughout), transitioned to high (≥13.5 µg/mL at any point), or intermediate (all others). Analyses used multivariable trajectory-based Cox regression, time-dependent Cox regression, and generalized estimating equations (GEEs), adjusting for chronic kidney disease, inferior mesenteric artery patency, and number of patent lumbar arteries (≥6). RESULTS: Among 118 patients, 43 (36.4%) experienced AnE. Kaplan-Meier analysis showed significantly lower freedom from AnE in the transitioned to high group (overall log-rank P = .002). In trajectory-based Cox regression, the transitioned to high group had significantly increased AnE risk versus the consistently low group (adjusted hazard ratio = 4.76, 95% confidence interval [CI]: 1.62-14.00, P = .005). Generalized estimating equation sensitivity analysis confirmed a dose-response relationship, with high D-dimer showing the strongest association (odds ratio 3.45, 95% CI: 1.69-7.05, P < .001). CONCLUSION: D-dimer dynamics were associated with AnE in patients with pT2ELs. Multiple complementary analyses demonstrated consistent dose-dependent associations. Retrospective trajectory classification defined distinct prognostic phenotypes: patients maintaining levels <5.3 µg/mL demonstrated superior sac stability, whereas elevations ≥13.5 µg/mL identified a higher-risk group. These findings support a biomarker-guided dynamic surveillance strategy, pending prospective validation before clinical deployment.Clinical ImpactCurrent surveillance of persistent type 2 endoleaks relies solely on imaging, lacking validated biomarkers to guide follow-up. This retrospective study shows that longitudinal D-dimer trajectory patterns were independently associated with aneurysm enlargement over 5 years, and D-dimer levels at each annual visit were associated with enlargement risk in the subsequent year. A routinely available blood test may therefore complement imaging-based surveillance: levels below 5.3 µg/mL were associated with low enlargement risk, whereas elevations ≥13.5 µg/mL defined a higher-risk phenotype warranting closer follow-up. If prospectively validated, this biomarker-guided approach could support individualized surveillance and more efficient use of imaging resources.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Sugimoto M, Kinoshita F, Osawa T, et al. Prognostic Value of D-Dimer Dynamics for Aneurysm Enlargement in Patients With Persistent Type 2 Endoleaks After Endovascular Aneurysm Repair. J Endovasc Ther. 2026. PMID: 42473158. doi:10.1177/15266028261467191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。